The Effect of PinnoThin on Satiety and Food Intake

Obesity Clinical Trial

— PinnoThin  

Official title:

The Effect of PinnoThin on Satiety and Food Intake

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01034605
• Other study ID #: HumBio_Westerterp08
• Status: Completed
• Phase: N/A
• First received: December 2, 2009
• Last updated: August 29, 2012
• Start date: December 2008
• Est. completion date: January 2010

Study information

• Verified date: August 2012
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

Based upon an increased secretion of gastrointestinal satiety hormones (CCK, GLP-1), PinnoThin is hypothesized to be more satiating, and to limit energy intake in humans. Therefore, the objective of this study is to investigate whether PinnoThin leads to an increase in satiety as determined by VAS ratings? Additionally, does PinnoThin consumed during breakfast, in comparison to placebo, in overweight women, lead to a decrease in energy intake during an ad libitum lunch?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: January 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• age over 18 and under 45

• women

• BMI over 23 and under 30

• breakfast eaters

Exclusion Criteria:

• men

• age under 18 and over 45

• BMI under 23 and over 30

• use of medication

• pregnant and breastfeeding

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Obesity

Intervention

Dietary Supplement:
• PinnoThin
6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose

Locations

Country	Name	City	State
Netherlands	Maastricht University	Maastricht	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	appetite profile ratings		10 timepoints	No
Secondary	energy intake		3.5 hours after PinnoThin	No